The global vaginal and vulval inflammatory diseases treatment market is expected to be worth USD 2.96 Billion in the fiscal year 2023, which rose up from USD 2.8 Billion in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 5.8% CAGR, reaching a value of USD 5.21 Billion by the end of 2033.
Both vulvitis (vulval inflammation) and vaginitis (vaginal inflammation) refer to inflammation of the female reproductive organs. Vulvitis is an infection of the genitals, or vulva - the outermost portion of the female reproductive anatomy. Vaginitis is an inside-the-body inflammation that damages the vagina. Vulvovaginitis is an inflammation that affects both the vulva and the vagina. These inflammatory disorders are typically brought on by yeast, candida species, or candida Albicans. Atypical vaginal discharge, dyspareunia, external dysuria, vaginal discomfort, and pruritis are a few signs of vaginal and vulval inflammation.
Approximately 75% of women are expected to have vaginal and vulval inflammation at least once, and 42% to 45% of women may experience the illness twice or more, according to statistics from the Centers for Disease Control and Prevention. Depending on the clinical presentation, the microbiology, the host characteristics, and the response to treatment, this illness is categorized as difficult or simple.
In most cases, the problem necessitates consulting a gynecologist or simply a nurse practitioner. Antifungal drugs can be used to diagnose and treat vaginal and vulval irritation. Although vaginal and vulval inflammation may usually be managed in a few days, more serious instances may require extended periods of therapy. Such factors have been boosting the treatment market for vaginal and vulval inflammations during the forecast period.
| Attributes | Details |
|---|---|
| Expected Market Value (2023) | USD 2.96 Billion |
| Projected Forecast Value (2033) | USD 5.21 Billion |
| Global Growth Rate (2023 to 2033) | 5.8% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global vaginal and vulval inflammatory diseases treatment market grew at a CAGR of 5.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. These kinds of diseases are quite common among the female population.
One of the main drivers of this market is the increasing cases of diabetic patients along with other infections such as yeast infections and STDs. Such infections spread quickly in the vulval and vaginal region, causing them to swell and develop irritation. Such rising cases have been propelling the market for the treatment of vaginal and vulvar diseases from 2023 to 2033.
As a result, the global vaginal and vulval inflammatory diseases treatment market is expected to forecast a CAGR of over 5.5% from 2023 to 2033.
Increasing the incidence of diabetes to boost the demand
A major reason for the occurrence of various kinds of vaginal and vulval inflammation is diabetes, particularly in Type 1 diabetic patients. All across the world, diabetes is becoming more and more common. According to WHO figures, there were around 109 million diabetic patients in 1980; by 2021, that number had increased to 822 million. Compared to high-income countries, the incidence has been increasing more quickly in low- and middle-income countries.
One of the causes of several significant problems, including vaginal itchiness, burning, and infection, is diabetes. About 8.7% of American individuals over the age of 18 had diabetes in 2020. The incidence of vaginal and vulval inflammatory illnesses is expected to rise along with the prevalence of diabetes worldwide. The market for treating vaginal and vulval inflammatory illnesses would rise as a result in the near future.
Increasing government initiatives and R&D to accelerate the growth
Many governmental and non-governmental groups, like the European Institute of Women's Health (EIWH) and Women's Health Organization, have launched campaigns to raise awareness of women's sexual health. The changing lifestyle patterns of women throughout the world, such as drinking and smoking use, and ongoing research and development efforts by various firms are the main drivers of market expansion.
Also, scientists were given funding by the National Institute of Allergy and Infectious Diseases (NIAID) to design the yeast infection test so that the right anti-fungal therapy could be given. Additionally, researchers from the Division of Intramural Population Health Research (DIPHR) at the NICHD are examining a variety of associations between bacterial vaginosis and pregnancy outcomes utilizing both previously collected and recently generated data. As a result, it is anticipated that further research and development will be done for precise diagnosis and boost the global market growth.
Side effects of a few medicines impede the global market
Antifungal drugs, including fluconazole, are used to treat candida infections such as vulvovaginal candidiasis as well as other vulval inflammatory diseases. Fluconazole can interact with many other blood thinners, sedatives, antibiotics, antiseizure drugs, diuretics, and other medicines. Furthermore, different warnings on the medicines are applied to those who have liver illnesses or other ailments that might lead to the negative effect of consuming such circumstances. Thus, such factors can impede the growth of this market and hence curtail the demand for the treatment of vaginal and vulval inflammatory diseases.
The rising incidence of STDs along with other vaginal diseases will boost the growth
North America is predicted to hold the dominant market share of 53% revenue share in 2023 and is the fastest-growing market for vaginal and vulval inflammatory disease treatment, with a dominant 6.4% CAGR from 2023 to 2033.
This predominance is primarily caused by rising rates of polycystic ovary syndrome, menopausal disorders, uterine fibroids, trichomoniasis, endometriosis, HIV/AIDS, etc. among women in the USA, which generates the highest amount of revenue in the region, as a result of changes in lifestyles and an increase in stress. For instance, the Centers for Disease Control and Prevention (CDC) reported in April 2022 that STDs continue to be a major public health problem in the nation. The study was titled Sexually Transmitted Disease Surveillance, 2020.
The same report says that with a number of 1,579,875 reported incidents to the CDC in 2020, Chlamydia trachomatis illness was the most common notifiable sexually transmitted infection in the USA. Infections with 677,869 distinct gonorrhea strains were reported to the CDC in 2020. Such increasing cases have resulted in various types of vaginal and vulval inflammatory diseases. Hence, during the forecast period, the North American region can be expected to show a significant growth rate.
The presence of major players and the rising incidence of diabetes accelerate the growth
During the forecast period, the Asia Pacific market for vaginal and vulval inflammatory disease treatment is expected to garner a steady CAGR of 5.8%. The dominance of the region within this industry is mostly due to the presence of companies like Pfizer Inc., Johnson & Johnson Services Inc., and others.
Additionally, the regional market is growing as a result of the region's increasing diabetes prevalence, which might result in a rise in the incidence of vaginal and vulval inflammatory illnesses in Asian countries. Asians have a significant ethnic and genetic propensity to diabetes, as well as lower risk variable thresholds. As a consequence, they develop diabetes at a relatively young age and have a lower BMI and waist circumference than the Western population. Such factors lead to the growth of various vaginal inflammatory diseases among women. Hence, factors such as these are expected to accelerate the growth in the market from 2023 to 2033.
The vaginal burning segment will gain the dominant market share
Over the course of the forecast period, the vaginal burning segment by indication type is anticipated to occupy a significant share of the global vaginal and vulval inflammatory disease treatment market. In 2023, this category is anticipated to dominate with a 53% revenue share.
These conditions appear as the microorganism gets in touch with the vagina and causes the area to swell up immediately, with extreme itching and burning sensations. Almost 8 out of 15 women have reported vaginal burning to be the primary symptom of vaginal and vulval inflammation diseases. Such factors are expected to accelerate the growth prospects for vaginal and vulval inflammatory disease treatment from 2023 to 2033.
The specialty clinics segment will demand during the forecast period
According to the research by Future Market Insights, the specialty clinic segments will gain popularity during the forecast period. It is anticipated that this segment will occupy a global market share of 25% from 2023 to 2033.
During a case of vaginal and vulval inflammation, patients prefer visiting a gynecologist at any clinic or nursing home meant only for women's sexual and reproductive health. This is mainly because the patients get a lot of options for the doctors to choose from and the same goes for their treatments as well. Hence, factors such as these are expected to propel the market growth during the forecast period.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The goal of the newly established firms in this industry is to apply a variety of methods, including the introduction of new goods and acquisitions, to strengthen their market positions globally. Additionally, a sharp increase in the amount of public financing available for the development of these medications is anticipated to fuel the market.
Another American femtech firm, Evvy, has entered the competition to collect data sets to aid in identifying and researching a variety of health conditions that might impact women. Evvy introduced an at-home test kit for the vaginal microbiota in 2022. The user sends their swab back to the business for processing, where they receive thorough details and assessment of the microorganisms (fungi and bacteria) prevalent in their vagina and potentially linked to a range of health issues or inflammations.
Some of the prominent players in the global market for vaginal and vulval inflammatory diseases treatment are:
Some of the prominent developments of the key players in the market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.8% from 2023 to 2033 |
| Market value in 2023 | USD 2.96 Billion |
| Market value in 2033 | USD 5.21 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Indication, Treatment, End-user, Region |
| Regions Covered | North America; Latin America; Asia Pacific; Oceania; Middle East & Africa |
| Key Countries Profiled | United States of America, Canada, Mexico, Brazil, Germany, Italy, France, United Kingdom, Spain, Poland, Russia, China, India, ASIAN, Australia, New Zealand, Japan, GCC Countries, South Africa, Northern Africa |
| Key Companies Profiled | Almirall; VenusConcept; ThermiGen LLC; Lutronic; BTL Group of Companies; Viveve; Fotona; Hologic; Kyung Hee University Hospital |
| Customisation Scope | Available on Request |
A market value of USD 2.96 billion is projected for 2023.
In 2033, North America is predicted to generate a CAGR of 6.4%.
By 2033, the market is expected to reach USD 5.21 billion.
The vaginal burning market is to account for 53% of revenue in 2023.
The Asia Pacific region is growing at a steady rate of 5.8% between 2023 and 2033.
| Current Valuation in 2024 | USD 3,328.9 million |
|---|---|
| Forecasted Valuation in 2034 | USD 5,230 million |
| Value CAGR (2024 to 2034) | 4.8% |
| Expected Market Value (2023) | USD 1035 Million |
|---|---|
| Projected Forecast Value (2033) | USD 1607 Million |
| CAGR (2023 to 2033) | 4.5% |
Explore Therapy Area Insights
View Reports
Vaginal and Vulval Inflammatory Disease Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
